MedTrace Logo

Decipher Genomics Resource for Intelligent Discovery

NCT02609269 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1000000

Last updated 2023-02-17

No results posted yet for this study

Summary

To prospectively evaluate the utility of genomic expression data as a tool to better characterize the tumors of individual patients, and to understand how genomic information from individual patients undergoing routine clinical testing can be used in population-level analysis to improve treatment and outcomes.

Conditions

Interventions

OTHER

Decipher Cancer Classifier

The Decipher are gene expression-based tests that are used to better risk stratify or characterize tumor biology that are commercially available through Veracyte, Inc CLIA \& CAP certified laboratory in San Diego, CA

Sponsors & Collaborators

  • Veracyte, Inc.

    collaborator INDUSTRY

  • GenomeDx Biosciences Corp

    lead INDUSTRY

Principal Investigators

  • Elai Davicioni, PhD · Veracyte, Inc.

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2030-12-31
Completion
2040-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609269 on ClinicalTrials.gov